What is US Biologic?
US Biologic is at the forefront of developing advanced oral vaccine delivery systems designed to combat infectious diseases in both human and animal populations. The company's technological focus addresses critical public health concerns, including pandemic preparedness and the prevention of prevalent diseases such as Lyme disease. Their innovative approach targets a broad spectrum of clients, encompassing healthcare providers, the agricultural sector, and animal health organizations, aiming to bolster global health security through enhanced vaccine accessibility and efficacy.
How much funding has US Biologic raised?
US Biologic has raised a total of $1.1M across 2 funding rounds:
Debt
$1M
Debt
$106K
Debt (2017): $1M, investors not publicly disclosed
Debt (2021): $106K led by PPP
Key Investors in US Biologic
PPP
Public-Private Partnership
What's next for US Biologic?
The recent major strategic investment signifies a pivotal moment for US Biologic, likely enabling the company to accelerate its research and development pipeline, scale manufacturing capabilities, and expand its market reach. This capital infusion is expected to propel the company's mission to enhance global health by providing more accessible and effective vaccine solutions, particularly in areas prone to infectious disease outbreaks. The enterprise-level funding context suggests a strategic phase focused on commercialization and broader adoption of their novel delivery platforms.
See full US Biologic company page
